An academic health center cost analysis of screening mammography by Chen, Steven L. et al.
An Academic Health Center Cost Analysis of
Screening Mammography
Creating a Financially Viable Service
Steven L. Chen, M.D., M.B.A.1,2
Samuel Clark3
Lori J. Pierce, M.D.4,5
Daniel F. Hayes, M.D.4,6
Mark A. Helvie, M.D.4,7
Paula L. Greeno, M.B.A.8
Lisa A. Newman, M.D.2,4
Alfred E. Chang, M.D.2,4
1 University of Michigan Center for Health Care
Economics, Ann Arbor, Michigan.
2 Department of Surgery, University of Michigan
Health System, Ann Arbor, Michigan.
3 Programs and Operations Analysis, University of
Michigan Health System, Ann Arbor, Michigan.
4 University of Michigan Comprehensive Cancer
Center, Ann Arbor, Michigan.
5 Department of Radiation Oncology, University of
Michigan Health System, Ann Arbor, Michigan.
6 Department of Internal Medicine, University of
Michigan Health System, Ann Arbor, Michigan.
7 Department of Radiology, University of Michigan
Health System, Ann Arbor, Michigan.
8 Office of the Executive Vice President for Medical
Affairs, University of Michigan Health System, Ann
Arbor, Michigan.
Address for reprints: Alfred E. Chang, M.D., De-
partment of Surgery, University of Michigan, 1500
East Medical Center Drive, 3302 Cancer Center,
Ann Arbor, MI 48109-0932; Fax: (734) 647-9647;
E-mail: aechang@umich.edu
Received February 29, 2004; revision received
May 25, 2004; accepted June 3, 2004.
BACKGROUND. The current study sought to determine the institutional financial
impact of a screening mammography (SM) program in the context of an integrated
cancer center.
METHODS. Using administrative databases, 10,048 women were identified as re-
ceiving screening mammograms in fiscal year 1999 and the first one-half of fiscal
year 2000. The utilization of breast care resources was followed for an average of
1208 days. The University of Michigan cost accounting system was then used to
determine overall margin (revenues  total costs) and contribution margin (rev-
enues  actual costs) of the SM program, as well as other breast care services.
RESULTS. The percentage of variable costs to total costs for the SM program was
24%. The overall facility losses in the breast care line were $1.7 million with a
positive contribution margin of $2.0 million. The annual yield of nonscreening/
diagnostic mammographic procedures was 0.9%. All types of radiologic activity
failed to cover their total costs, but did provide a positive contribution margin.
Overall margins for surgery procedures were approximately even, and adjuvant
medical and radiotherapy services were net positive. Modeling helped to identify
overhead limits necessary to achieve margin targets associated with increased
activity.
CONCLUSIONS. The current study showed that SM programs are unlikely to succeed
financially without careful selection of those screened to increase the yield of
diagnostic and therapeutic procedures. Based on favorable contribution margins,
SM programs were viable when viewed as incremental business. Cancer 2004;101:
1043–50. © 2004 American Cancer Society.
KEYWORDS: cost analysis, mammography, breast care, cancer screening.
There have been few public health screening activities that havebeen as highly debated and heavily publicized as screening mam-
mography. Large population studies have demonstrated decreased
breast carcinoma mortality in groups screened using mammography.
At the same time that advocates have encouraged an expansion of
screening, mammography screening centers have been closing with
124 centers closing between October 2002 and May 2003 alone.1 Many
cite a lack of remuneration and high professional liability risks as the
reason for this decline.2 A study by Enzmann et al.3 demonstrated that
at least on the professional fee side, reimbursement did not even
cover the costs of performing the examination. However, little is
known as to whether the same is true for a hospital or radiology
center.
We undertook the current study to examine the financial impact
of a mammographic screening program within an academic health
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center. The analysis excluded professional reimburse-
ments and focused on the facility reimbursement. We
hypothesized that screening mammography, despite
being potentially unprofitable, would generate subse-
quent visits to higher profit centers within the hospital
such as interventional radiology, surgery, medical on-
cology, and radiation oncology that would offset the
losses on screening mammography.
MATERIALS AND METHODS
Patient Population
Patients were assigned coded numbers to eliminate
patient identifiers. The University of Michigan institu-
tional review board approved a waiver of consent. All
patients receiving screening mammograms in fiscal
year (FY) 1999 and the first one-half of FY2000 (n
 10,048) at the University of Michigan Health System
(UMHS) were identified for the study using the hos-
pital cost accounting system (TSI [Eclipsys], Boca Ra-
ton, FL). These were patients who underwent an out-
patient visit using only a single resource logged as
“screening mammography– bilateral,” which is spe-
cific for patients who have had no previous risk factors
for breast diseases (e.g., history of breast mass, strong
family history, previous breast biopsies, or malignan-
cies). Patients who received both a diagnostic mam-
mogram and a screening mammogram on the same
day were logged as diagnostic mammograms. For the
purposes of the current study, we also included pa-
tients with bilateral diagnostic mammograms who did
not have a diagnosis of previous breast pathology.
Patients referred for second opinions or outside
screening mammograms were excluded. This yielded
10,048 distinct patients.
Resource Utilization
Patients were tracked for resource utilization of breast
care services from their index visit (their first screen-
ing mammogram in FY1999 or the first one-half of
FY2000) through May 31, 2002. This provided a 2–3-
year follow-up of resource utilization. Costs as expe-
rienced by the institution were derived using the Uni-
versity of Michigan Health System Data Warehouse
(HSDW), which contains data on all outpatient and
inpatient visits within the UMHS from 1996 to the
present. Costs were split into variable direct costs (i.e.,
costs such as radiographic film supplies, pharmaceu-
ticals, and other supplies used), fixed direct costs (i.e.,
fixed costs of nonhourly staff required to run a unit
and local capital expenditures such as radiography
equipment), and indirect costs (i.e., general institu-
tional overhead such as hospital executive compensa-
tion and portion of financing). Revenues were derived
from the HSDW based on the historically based esti-
mated net revenue that each patient’s insurance pro-
vider generally provided to our institution for each
service. Charges were also tracked using actual billed
charges. Overall margin was defined as the difference
between revenue and total costs. Contribution margin
was defined as the difference between revenue and
variable costs (i.e., actual costs).
Subsequent visits by defined patient cohorts and
the timing of those visits were identified through the
accounting systems and breast care items were man-
ually abstracted. We defined diagnostic mammogra-
phy as all mammography that was not listed with the
identifier, screening mammography– bilateral. This in-
cluded all unilateral mammograms, and mammo-
grams that were listed with a nonscreening diagnosis.
Interventional radiology included all breast biopsies
performed in the radiology suites that were identified
by procedure codes (e.g., ICD-9) and/or supply codes
(an internal cost accounting mechanism). Surgery in-
cluded all procedures performed on the breast subse-
quent to an initial screening mammogram as identi-
fied by appropriate ICD-9 codes. Medical oncology
included all chemotherapy infusions and radiation
oncology included all visits for external-beam radia-
tion, both identified by a combination of procedure
codes and supply codes. Other cancers were excluded
by matching the interventions with an appropriate
breast carcinoma diagnosis code.
For the purposes of grouping, inpatient encoun-
ters were bundled into one visit, and all related labo-
ratories performed on the day of outpatient interven-
tion encounters (e.g., interventional radiology,
surgery, medical oncology, and radiation oncology)
were bundled into the encounter statistics. The index
screening mammogram for each patient was defined
as Time 0, and all time points were calculated from
that point.
Modeling Methods
Modeling of the impact of changing various parame-
ters was performed using Microsoft Excel 2000 (Mi-
crosoft, Bellevue, WA). To analyze the impact of
TABLE 1
Patient Demographics
Age (yrs) No. of patients (%)




 69 1138 (11.3)
Total 10,048 (100.0)
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changing payer mix, patients were subtracted from the
test group and redistributed using the proportions of
each other type of payer for that specialty’s services.
To analyze the impact of changes in yield, the overall
3-year yield was varied for all subsequent services
beyond screening mammograms, using the assump-
tion that their relative utilizations would stay constant
(i.e., the proportion of operations to chemotherapy
visits was held constant). A comparison of age groups
was performed starting after Year 1, which was ex-
cluded to minimize potential bias from referral pat-
terns into our health center. Productivity improve-
ments were modeled by doubling overall screening
populations, doubling variable costs, and varying the
amount of overhead assigned to each service.
RESULTS
Patient Demographics and Yield of Follow-Up Services
Demographic data of our patient population demon-
strated a fairly typical screening population, with
45.7% of patients being  50 (Table 1). Follow-up
utilization of mammography services exhibited nu-
merous spikes in usage (most notably at yearly inter-
vals). However, 32.5% of patients initially screened did
not return to our institution for any breast-related care
in the follow-up time period (Fig. 1). Patients requiring
a subsequent diagnostic mammography visit showed
a fairly steady accumulation, with 28.5% requiring  1
nonscreening mammogram during the follow-up pe-
riod.
For the total time followed, 3.1% of patients re-
ceived  1 nonscreening, nondiagnostic mammo-
graphic service, for an annual average of 0.9% of pa-
tients per year (Fig. 2). Some patients with a
subsequent diagnosis of cancer may have had services
rendered by multiple disciplines. When broken down
to services rendered by each discipline, 3.1% of pa-
tients received a procedure in radiology, 2.1% subse-
quently received  1 surgical procedure, 0.5% re-
ceived services from medical oncology, and 0.4%
received services from radiation oncology. These non-
screening/diagnostic mammographic service yields
differed when the cohort was split by age group. In
Years 2 and 3, patients  50 years averaged an annual
yield per patient of 1.1% whereas patients  50 years
averaged 0.9%.
FIGURE 1. Return mammography utilization.
FIGURE 2. Yield of nonmammographic services. MMG: mammography.
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Margin Analysis
The average variable cost per screening mammogram
for the initial period was $20.47. The aggregate overall
margin for the initial screening mammogram service
was $921,359. However, the contribution margin
was $205,340, indicating that the service does cover its
actual costs, but not the total overhead that is attrib-
uted to it (Table 2). Of all breast care-related services,
only radiation oncology and medical oncology yielded
a profit based on overall margins. Other radiology
services such as interventional radiology (including
biopsies) as well as diagnostic mammography (all
nonscreening mammograms) operated at a loss over-
all (Table 2). Notably, the screening mammography
program submitted aggregate charges that were less
than total costs, whereas therapeutic specialties such
as surgery, medical oncology, and radiation oncology
submitted charges far in excess of costs. Collection
rates were similar across specialties, except for medi-
cal oncology, which collected approximately 67% of its
charges.
A breakdown by types of payer demonstrated
widely differing margins for any given service (Table
3). Some payers yielded a positive overall margin for
some services, whereas others were consistently neg-
ative across all services. Capitated health maintenance
organizations (HMOs) represented the lowest group of
payers, with no patients covering their total allocated
costs. Commercial payers as well as Blue Cross/Blue
Shield indemnity plans tended toward the best mar-
gins.
Fixed costs were broken down into unit-specific
overhead and hospital overhead for each service via
the cost accounting database that uses an activity-
based cost system. Unit-specific overhead varied from
40% to 76% of the total overhead assigned, with an
overall average of 50% (Fig. 3).
Scenario Modeling
In modeling service expansion scenarios, we consid-
ered the impact of various levels of overhead expan-
sion if screening populations were doubled at the
outset. Our model (Fig. 4) demonstrated that to ensure
that margins did not worsen for the entire breast care
center, overhead would have to expand at  54% if
volumes were doubled. Smaller overhead expansions
lead to better margins, with a 7.7% overhead expan-
sion allowing the entire center to become a break-
even (overall margin  0) proposition.
Financial modeling estimated that for each 10% of
all patients that can be shifted away from capitated
contracts to noncapitated contracts, $238,355 could
be gained in overall margins over the period studied,
assuming that all other variables (i.e., total volume,
charges, and yields) were held constant. Eliminating
the HMO patients entirely, while keeping all else equal
including the other relative payer mix, still resulted in
an overall negative margin of $423,425. This would
TABLE 2
Cost Breakdown by Service
Characteristics Index mammogram Follow-up screening Diagnostic mammography Interventional radiology
No. (unique patients) 10,048 6,769 2,863 313
Total cost $1,332,386 $1,131,531 $653,866 $323,794
Variable cost $205,687 $212,257 $127,419 $94,156
Charges $896,524 $1,278,698 $887,355 $332,075
Revenue $411,027 $605,963 $438,555 $154,532
Margin $921,359 $525,568 $215,311 $169,262
Contribution margin $205,340 $393,706 $311,136 $60,376
Charge/cost ratio 67% 113% 136% 103%
Collection rate 46% 47% 49% 47%
Surgery Medical oncology Radiation oncology Total
No. (unique patients) 201 37 51 10,048
Total cost $763,420 $356,185 $376,164 $4,937,346
Variable cost $272,040 $198,945 $75,084 $1,185,588
Charges $1,523,449 $645,093 $1,034,838 $6,598,032
Revenue $708,262 $429,181 $459,056 $3,206,577
Margin $55,158 $72,996 $82,892 $1,730,769
Contribution margin $436,222 $230,236 $383,972 $2,020,989
Charge/cost ratio 200% 181% 275% 134%
Collection rate 46% 67% 44% 49%
HMO: Health Maintenance Organization.
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indicate that the payer mix change would either need
to be targeted to fill the gap or that the payer mix
would need to be combined with other changes to
reach a break-even result. Modeling based on poten-
tial yield changes demonstrated that if the yield could
be increased from 3.1% to 4.1% (chosen to correspond
to the 32% increased risk of developing breast carci-
noma in women 50 – 60 years old),4 contribution mar-
gins would improve by $1,054,068 when all other vari-
ables were held constant. However, without some
savings in overhead, or changes in the relative yields of
the nonradiologic procedures compared with diagnos-





























Capitated HMOs $84 $11 51.5 $76 $32 48.1% $592 $3 51.3
Blue Cross/Blue Shield $45 $52 23.0 $8 $98 26.6 $283 $352 27.3
Commercial $42 $55 11.9 $3 $113 12.1 $236 $311 9.1
Medicare $67 $29 13.2 $43 $63 12.9 $403 $319 12.0
Medicaid $70 $26 0.3 $59 $47 0.3 $541 $147 0.3

























Capitated HMOs $1058 $466 58.8 $286 $157 58.5 $959 $4,351 64.9
Blue Cross/Blue Shield $1202 $2581 24.8 $1060 $1866 22.6 $6404 $11,853 28.1
Commercial $1391 $2758 8.1 $1357 $1916 15.3 $4093 $8256 5.3
Medicare $545 $1934 8.4 $216 $226 12.8 $3631 $8567 1.8
Medicaid 0.0 0.0 0.0
HMO: health maintenance organization.
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tic and further screening, expansion of volume would
not improve overall margins.
A break-even analysis was performed. Break-even
results could be achieved by improving revenues per
service or by lowering the cost of each service (Fig. 5).
For total costs, a 35% reduction across the board
would bring overall margins to zero. For revenues, a
hike of 54% would be required to reach a break-even
result, assuming that all other items (i.e., volume,
payer mix, costs) remained constant.
DISCUSSION
Few public health measures in the United States have
engendered as much passion and discussion as
screening mammography. The majority of studies
have demonstrated a mortality benefit for populations
screened, with the impact varying by the underlying
risk factors such as age and family history.5 Advocates
have pushed for improving access to screening mam-
mography across the entire eligible population in an
attempt to bring the benefits of this intervention to as
many women as possible. Simultaneously, however,
screening mammography programs are scaling back
or closing altogether, with the result being backlogs at
the remaining centers.6 The causes for this reduction
in supply, even in the face of burgeoning demand, are
attributed, at least in part, to poor reimbursement and
high costs of providing this service, particularly in the
professional liability climate of today.7 Our study
demonstrates one possible reason why facilities may
not be interested in filling the gap.
Our study demonstrates the difficulties in running
a dedicated screening mammography unit. The losses
incurred by screening mammograms alone during the
index period were $921,359. More importantly, no
payer reimbursed sufficiently to cover the overhead
associated with performing the procedure for any
given patient. Reimbursements by national payers
FIGURE 5. Break-even analysis.
FIGURE 4. Overhead expansion versus overall margin.
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were comparable to published fee schedules by Medi-
care, which ranged from  $60 per mammogram to
approximately $80 in the most recent fee schedule. By
only covering the variable costs, screening mammog-
raphy would only be a profitable service when consid-
ered as a purely incremental service, i.e., to fill excess
capacity that is not used by other radiologic services.
However, because virtually all mammography units
are running at capacity and most have significant
backlogs, this strategy dooms screening to a position
where there will never be enough capacity to meet
demand.
Alternately, we have shown that an integrated
cancer center can use mammography services to gen-
erate profitable services (i.e., medical oncology and
radiation oncology), which can potentially subsidize
the losses incurred by the unprofitable service,
namely, screening mammography. Careful control of
a number of factors is required to utilize this pathway
to financial viability when providing mammography
services. First, a focus on yield is key to maintaining a
logical connection between mammograms and prof-
itable cancer treatments. When capacity is limited, a
focus on high-risk patients who will undergo more
diagnostic and therapeutic interventions beyond just
screening should be considered. This will allow cancer
centers to utilize their limited resources to better fulfill
their missions of outreach to the community in de-
tecting cancers, as well as treating cancers as they
occur. It is important to recognize that this situation
also matches what most people would consider opti-
mal triage, namely, prioritizing high-risk patients to
receive a limited resource first. Another aspect of
screening mammography that we did not analyze was
the impact the screened population would have on the
medical institution for referral of non– breast-related
services. This was beyond the scope of the current
study.
Next, a focus on payer mix and relative reimburse-
ment rates is important to achieve financial viability. It
is noteworthy that for radiology services, our institu-
tion typically charged close to the total cost of care.
Given our 46 – 49% collection rate, this was a key fi-
nancial disadvantage. A reexamination of charges is
an important component of rationalizing the financial
situation. Furthermore, in capitated contracts where
charges are irrelevant, the allocation of the contract
monies internally should recognize the importance of
screening mammography as the portal to other forms
of care. When health centers have captive or preferred
health plans, it is important to consider the effect of
the transfer price applied between the two units as
well. Setting these prices too low will make the clinical
unit appear to be doing poorly and will discourage the
unit from seeking out patients who come from this
insurance group. In our case, our own capitated HMO
was indeed ranked as the lowest payer, and the pre-
ponderance of these patients significantly impacted
the overall finances of the entire breast center as it
related to the screened population. Our modeling
demonstrated that small shifts of patient population
groups could make an impact in the overall bottom
line.
Finally, the issues of throughput and fixed asset
productivity need to be considered. In our institution,
the contribution margins were positive, whereas the
overall margin was negative. Our variable costs com-
prised 24% of the total costs in contrast to other insti-
tutions, which have reported variable costs as low as
15% of the total costs.8 Low variable costs relative to
total costs mean that an unprofitable service may,
indeed, result in eventual profits. This is only true,
however, when allocated fixed costs do not increase as
fast as volume increases. To the extent that reengi-
neering the process can allow mammography centers
to perform more examinations out of their existing
infrastructure, or only expand part of their infrastruc-
ture (e.g., by increasing the clinical staff, but not in-
creasing the administrative staff), the losses in mam-
mography centers will decrease. Our modeling
indicated that increasing our clinical volume with pro-
jected limits on overhead increases would allow the
breast care center to improve financially. Productivity
must be balanced against quality and it would be
foolhardy for a system to exceed its capacity, thus
leading to poorer outcomes. However, to the extent
that inefficiencies in care delivery can be avoided,
better financial outcomes may be matched with an
equivalent or better clinical outcome.
Our study contains an assumption that is impor-
tant to highlight. We used a rules-based accounting
system that divides costs into variable, fixed direct,
and indirect costs. Although we have used these rules
for planning and evaluating the performance of our
clinical units, no cost accounting system can give a full
picture of what truly occurs within any complex sys-
tem. Thus, some items that are variable in one respect
(e.g., computer time used to type a dictation report)
are often considered to be fixed for simplicity. This
may introduce bias into the profitability of one unit of
the hospital compared with another. However, be-
cause these are the data that our finance department
uses in developing strategic plans, we believe that
these are the relevant data to use. If other institutions
were to utilize different accounting assumptions, they
may develop different conclusions regarding the bal-
ance between contribution and overall margins. Fur-
thermore, our status as an academic health center
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necessarily complicates our accounting system be-
cause revenues for the institution can come from dif-
ferent sources. We have chosen to focus the current
analysis on clinical revenues. Our accounting system
posts costs by each item used and service provided,
which best matches clinical costs with clinical reve-
nues. Occasionally, research needs may necessitate
running a loss in any one service, which could poten-
tially be made up for in research revenues that exceed
costs to the facility. This situation should be analyzed
separately from the clinical cost/revenue picture be-
cause it would still be important to recognize that the
service does not pay its own way.
The generalization of our specific data is also dif-
ficult to determine. Although nationwide reports from
both private and public providers have stated that
reimbursements are inadequate, every hospital works
within a cost milieu that may not be similar to ours in
the cost of equipment, labor, or the ease of acquisition
of patients. Other facilities may be able to negotiate
lower costs or garner higher reimbursements. There-
fore, instead of presenting our data as representative
of cancer centers across the country, we demonstrate
the key factors that determine the profitability of a
screening mammography program in an integrated
cancer center. Given our data, it would certainly be
more profitable to not perform screening mammog-
raphy at all if we could continue to operate at capacity
in performing cancer therapies. However, given that
screening programs have been proven to reduce
breast carcinoma mortality rates, the relevant ques-
tion that we faced is, “How can the provision of this
service be justified financially?”
Providing screening mammography services will
continue to be a challenge as poor reimbursement will
most likely continue in this era of cost-cutting by
insurers and rapid increases in health care costs paid
by our patients. It is likely that small mammography
units will continue to struggle in this milieu. Centers
that provide integrated cancer services will most likely
have to take up the slack. Attention to the guideposts
of appropriate charges, yield, payer mix, and produc-
tivity may help these surviving centers avoid similar
fates.
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